Organ transplantation is effective therapy for several types of organ failure. In the United States alone, approximately 200,000 patients survived transplantation between 1988 and 1997 [1] . Renal (12,000/y), liver (6,300/y), and heart (4,300/y) transplants are the most common. For patients transplanted between 1998 and 1999, 1-year survival is 98% for living related kidney recipients, 88% for liver recipients, 86% for cardiac recipients, and 75% for lung recipients [1, 2] . Five-year survival averages 91% for living related kidney recipients, 74% for liver recipients, 70% for cardiac recipients, and 44% for lung recipients [1, 2] . Patients transplanted now can expect to survive more than 10 years.
The advances in immunosuppressive therapy contributing to these improved outcomes have also brought new therapeutic challenges in the long-term management of these patients. Among these is a form of bone disease characterized by rapid bone loss and an extremely high rate of fractures [3••,4-6,7••]. This bone disease is primarily related to posttransplant immunosuppression with glucocorticoids and newer agents such as cyclosporine or tacrolimus. These drugs appear to have both independent and interrelated skeletal effects. Most authorities agree that transplantation osteoporosis is a form of glucocorticoid-induced osteoporosis. However, transplantation osteoporosis differs from the more typical form in several respects. Transplantation osteoporosis is often superimposed on significant pretransplant bone disease. In addition, the skeletal effects of glucocorticoids may be exacerbated by concomitant administration of cyclosporines or tacrolimus. Renal insufficiency and secondary hyperparathyroidism are common after organ transplantation and may contribute to bone disease. Most studies suggest that transplantation osteoporosis is a form of high-turnover bone disease, whereas glucocorticoidinduced osteoporosis is characterized as a low-turnover state.
This review discusses the contributions of various immunosuppressive medications to the pathophysiology of posttransplantation bone disease, the clinical features of osteoporosis in different types of organ transplantation, and the prevention and treatment of osteoporosis in this unique group of patients. tion over several weeks and transient increases during rejection episodes. Dosage varies with the organ transplanted, the number and management of rejection episodes, and the particular transplant program. Although the introduction of cyclosporine A, tacrolimus, and, more recently, sirolimus and daclizumab have permitted more rapid lowering of glucocorticoid doses [3••,6], there is still sufficient exposure to glucocorticoids, particularly in the first few months, to cause bone loss.
Glucocorticoids are known to decrease bone mineral density (BMD), and even small doses (equivalent to 2.5-10 mg prednisone) can increase fracture risk [8•,9••,10]. Bone loss is most rapid during the first 12 to 18 months and predominantly affects sites rich in trabecular bone (ribs, vertebrae, and distal long bones) [6,9••,10,11]. Glucocorticoid-induced osteoporosis is characterized by direct and profound reductions in bone formation [12, 13] and relatively minor increases in bone resorption [11, 13, 14] . The effects on resorption are primarily indirect, mediated both by secondary hyperparathyroidism caused by reduced intestinal and renal calcium absorption [8•,10,15-17], and by reduced synthesis of gonadal steroids [10,18].
Cyclosporine
Since cyclosporine was introduced in the early 1980s, there has been a marked reduction of rejection episodes and an improvement in graft survival [19] . Cyclosporine inhibits T-cell function via suppression of regulatory genes expressing products such as interleukin-2, interleukin receptors, and the proto-oncogenes H-ras and c-myc [19] [20] [21] . Animal studies strongly suggest that cyclosporine has independent effects on bone and mineral metabolism that could contribute to bone loss after organ transplantation [21] . Studies in the rat showed that severe bone loss, which was dose-dependent and duration-dependent and preferentially affected trabecular bone, resulted from cyclosporine administration [21] [22] [23] [24] . In contrast to glucocorticoid-induced osteoporosis, cyclosporine was associated with marked increases in both bone resorption and bone formation (high bone turnover), and with increased levels of osteocalcin [21, 23] , have been shown to alleviate cyclosporineinduced bone loss. These data suggest that cyclosporine may contribute to the high-turnover aspects of the bone disease seen after organ transplantation. In contrast, other researchers have reported a lack of bone loss in 13 renal transplant patients receiving cyclosporine in a steroid-free regimen [31] . It has been difficult to study the isolated clinical effects of cyclosporine on the human skeleton, because cyclosporine is usually used in conjunction with glucocorticoids.
Tacrolimus
Tacrolimus or FK506, a fungal macrolide, inhibits cytokine gene expression, T-cell activation, and T-cell proliferation [21] . Histomorphometric studies in the rat showed severe trabecular bone loss with FK506 [32] . A more recent rat study found that FK506 was associated with lower deoxypyridinoline excretion and less trabecular bone loss than cyclosporine [33] . Few studies have evaluated the skeletal effects of FK506 in humans. Both cardiac [34] and liver [35] recipients have sustained rapid bone loss with FK506-based immunosuppression. However, other researchers have noted decreased bone loss with FK506 [36, 37] . A recent study of liver transplant recipients found that those receiving FK506 had significantly higher femoral neck (FN) BMD 2 years posttransplantation than those receiving cyclosporine [37]. Cumulative glucocorticoid dose was significantly lower in the FK506-treated group, suggesting that the ability to lower steroids more rapidly may benefit the skeleton.
Other agents
Limited information is available regarding the effects of other immunosuppressive drugs on BMD and bone metabolism. Azathioprine, sirolimus, and mycophenolate mofetil do not cause bone loss in the rat model [38] [39] [40] . The skeletal effects of newer agents such as daclizumab have not been studied.
Clinical features of transplantation osteoporosis

Renal transplantation
Chronic renal failure is usually associated with some form of renal osteodystrophy (hyperparathyroidism, osteomalacia, adynamic bone disease caused by accumulation of aluminum and other compounds, osteosclerosis, ␤-microglobulin amyloidosis). Hypogonadism and certain medications (loop diuretics, heparin, glucocorticoids, or cyclosporine) also affect bone health before transplantation. In dialysis patients, the prevalence of low BMD is increased at the spine, hip, and distal radius Cross-sectional studies of patients evaluated several years after transplantation also report low BMD. Osteoporosis (defined as a BMD Z score Յ -2 or a T score Յ -2.5) has been found in 17 to 36% at the lumbar spine (LS) and 10 to 58% at the FN [46-52]. It is more severe in insulin-dependent diabetic patients receiving kidneypancreas transplants. [49] .
Longitudinal studies show that most bone loss occurs in the first 6 to 18 months after transplantation [53] [54] [55] [56] [57] [58] . The amount of bone loss ranges from 3 to 10% at the LS and 5% at the FN. Some studies report gender differences in the site of bone loss, with men losing more bone at the hip [56, 57] . The relation of bone loss to glucocorticoid dose, rejection episodes, activity level, patient age, and gender vary considerably.
Fractures affect appendicular sites (hips, long bones, ankles, feet) more commonly than axial sites (spine and ribs) [ 
Cardiac transplantation
Low BMD is common in severe congestive heart failure [65-67]. LS osteopenia (T score Յ -1.0) was found in 43% of patients and osteoporosis (T score Յ -2.5) in 7% of patients with congestive heart failure awaiting heart transplantation [67] . Vitamin D deficiency (low 25-OHD and/or 1,25(OH) 2 D levels) and secondary hyperparathyroidism were also common. Urinary markers of bone resorption were increased.
Low BMD is also common after cardiac transplantation. Approximately 2 years after transplantation, LS and FN Z scores less than or equal to -2 were found in 28% and 20%, respectively [ observed significant increases in intact parathyroid hormone, albeit within the normal range, during the first 3 months. The high turnover state documented after liver transplantation [97,104,106-108] contrasts with decreased bone formation and low turnover seen before transplantation [108] . This change from low to high bone turnover may be caused by resolution of cholestasis, use of cyclosporine or FK506, increased parathyroid hormone, or a combination of factors.
Lung transplantation
Lung transplant patients may have the most severe pretransplantation osteoporosis. Hypoxia, hypercapnia, tobacco, and glucocorticoids all may contribute. Cystic fibrosis is associated with additional risk factors for bone disease (pancreatic insufficiency, vitamin D deficiency, calcium malabsorption, hypogonadism) [109] . Densitometric osteoporosis has been reported in 29 to 50% of patients with end-stage pulmonary disease [110] [111] [112] [113] [114] [115] . Vertebral fractures were documented in 29% of patients with emphysema and 25% of patients with cystic fibrosis [113] .
Lung transplant recipients are even more severely affected; in one study, 73% had osteoporosis (Z score Յ -2) [110] . During the 1st year, rates of bone loss at the LS and FN were 5% [115, 116] . Fracture rates are also high during the 1st year, ranging from 18 to 37% [116, 117] . Some [110, 115, 116] but not all [114, 117] studies have found that bone loss correlates with corticosteroid dose. Bone turnover markers are consistent with increased resorption [118] and decreased formation [117] . Histomorphometric data from transplanted and nontransplanted cystic fibrosis patients show evidence of increased osteoclastic and decreased osteoblastic activity [119] .
Prevention and management of osteoporosis
Before transplantation
Bone mineral density of the hip and spine should be measured before transplantation whenever possible. Spine radiographs should be performed to detect prevalent fractures. If BMD is low, evaluation for secondary causes of osteoporosis should be undertaken. This evaluation should include serum electrolytes, calcium, phosphorus, creatinine, alkaline phosphatase, intact parathyroid hormone, and vitamin D metabolites. Gonadal, thyroid, and adrenal function should also be assessed. Urinary calcium and markers of bone turnover may be measured, if desired. Secondary causes of osteoporosis should be treated specifically. All patients should receive the recommended daily allowance of calcium and vitamin D. Hormone replacement therapy should be considered for postmenopausal women and premenopausal women with amenorrhea. Patients with renal failure should be evaluated and treated for renal osteodystrophy [120] .
Whether therapy for osteoporosis before transplantation reduces fracture risk after transplantation is unknown. However, antiresorptive therapy clearly increases BMD and reduces fracture rates in other populations [121, 122] . Therefore, individuals with osteoporosis or osteopenia awaiting transplantation should be evaluated and treated similarly to others with these conditions. The pretransplant waiting period is often long enough (1-2 years) to achieve significant improvements in BMD.
After organ transplantation
Studies have shown consistently that bone loss is most rapid immediately after transplantation. Fractures also occur very early and affect patients with both low and normal pretransplantation BMD. Therefore, the authors believe that most patients (even those with normal BMD) should have preventive therapy instituted immediately after transplantation. Currently, available therapies include antiresorptive drugs (bisphosphonates, calcitonin, and estrogen) and vitamin D metabolites. Because resorption markers are increased after transplantation, antiresorptive therapy is the logical choice.
Bisphosphonates
Bisphosphonates inhibit osteoclastic bone resorption and prevent osteoblast apoptosis [123] . They are approved for both treatment and prevention of glucocorticoidinduced bone loss [122, 124, 125] , and have been used successfully to treat established bone loss in renal transplant patients [126] . Several studies [127•,128-131] suggest that bisphosphonates prevent bone loss and fractures after transplantation. In an open-label study, a single intravenous dose of pamidronate, followed by cyclic etidronate (every 3 months) and daily oral calcitriol prevented LS and FN bone loss and reduced fracture rates in heart transplant recipients compared with historical control subjects [131] . Repeated doses of intravenous pamidronate in heart [128, 132] , renal [129] , and lung transplant recipients [114,127•] have been shown to prevent LS and FN bone loss. Some researchers have reported fracture reduction [133], whereas others [127•] have not. Initial studies evaluating early prophylaxis with oral bisphosphonates used cyclic etidronate [134, 135] in heart and liver transplant recipients and found no benefit in terms of bone loss or fracture risk. A more recent study found a protective prophylactic effect of etidronate in lung and heart recipients when compared with historical, untreated control subjects (although significant bone loss occurred in both groups) [136•]. In a small study [130] , alendronate increased LS BMD by 6.3% in six kidney transplant recipients, whereas 14 patients who received calcium carbonate and calcitriol sustained a 5.8% decrease over the first 6 months. Trials of alendronate for the prevention of osteoporosis in heart transplant recipients are underway.
In the opinion of the authors, bisphosphonates are the most promising approach to the management of transplantation osteoporosis. However, controversies remain regarding optimal administration of bisphosphonates. These include whether continuous or intermittent therapy should be used, duration of therapy, the level of renal impairment at which bisphosphonates should be avoided, whether they are safe in renal transplant recipients with adynamic bone disease, and their utility after pediatric transplantation.
Vitamin D and analogues
Vitamin D metabolites may reduce posttransplantation bone loss by reversing glucocorticoid-induced decreased intestinal calcium absorption and by mitigating secondary hyperparathyroidism [137] . They may also reduce glucocorticoid requirements through their immunomodulatory effects [137] [138] [139] .
It is clear that 400 to 800 IU of parent vitamin D does not prevent transplantation osteoporosis [7••,69]. However, bone loss is reduced in transplant populations treated with calcidiol [140, 141] Hypercalcemia and hypercalciuria, the major side effects of vitamin D, may develop at any point during the course of treatment. Frequent monitoring of urine and serum are required. In the opinion of the authors, active metabolites of vitamin D are not a first-line treatment for transplantation osteoporosis.
Calcitonin
Calcitonin increases BMD in patients with high-turnover osteoporosis [147, 148] . In the rat, calcitonin prevents cyclosporine-induced bone loss [29] . However, calcitonin is relatively ineffective in preventing bone loss after transplantation [3••,71,141,149].
Gonadal hormone replacement
Hormone replacement therapy may improve BMD in women treated with glucocorticoids [10]. Estrogen [27] and raloxifene [28] prevent cyclosporine-induced bone loss in the rat. Hormone replacement therapy significantly increased BMD in women with ovarian failure after bone marrow transplantation [150] and in postmenopausal women at more than 6 months after liver transplantation [151] . It has also prevented bone loss in women after lung transplantation [114] . Although hormone replacement therapy alone will probably not completely prevent bone loss in the 1st posttransplant year, there may be some protective benefit. However, hormone replacement therapy is probably unnecessary if bisphosphonates are given.
Hypogonadism also causes osteoporosis in men. In cardiac transplant recipients, testosterone has been shown to decline immediately after transplantation and normalize after 6 to 12 months. However, approximately 25% of men had biochemical evidence of hypogonadism at 1 to 2 years posttransplantation. Men with true hypogonadism should receive testosterone replacement. Prostatic hypertrophy, hyperlipidemia, and abnormal liver enzymes are potential risks of testosterone therapy.
Conclusions
Bone fragility and fractures are a significant cause of morbidity in the organ transplant population. The pathogenesis of transplantation bone disease is complex and incompletely understood. The immediate posttransplant period is characterized by rapid bone loss and fragility fractures, increased bone resorption, and decreased formation. Glucocorticoids combined with cyclosporine or FK506 contribute to this high-turnover state.
Ideally, all patients should have skeletal evaluation before transplantation and should receive preventive therapy for osteoporosis after transplantation. Because there are no pretransplantation variables that reliably predict posttransplantation bone loss and fracture, all patients are at risk for posttransplantation bone loss and fractures. Preventative therapy should be instituted immediately after transplantation, because most bone loss occurs in the first months after grafting. Bisphosphonates are the most promising approach for prevention and treatment of transplantation osteoporosis. 
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